Daily Endocrinology Research Analysis
Analyzed 86 papers and selected 3 impactful papers.
Summary
Three impactful endocrinology-related studies stood out today: a network meta-analysis shows CPAP most effectively reduces AHI in OSA while GLP-1 RAs primarily improve metabolic measures; a UK Biobank cohort reveals osteoporotic fracture risk rises when MASLD coexists with low muscle strength; and a large real-world case-control study identifies multi-morbidity and demographic predictors of progression from prediabetes to type 2 diabetes.
Research Themes
- Sleep-disordered breathing management and metabolic therapies
- Liver-muscle-bone interplay in fracture risk
- Risk stratification for diabetes prevention using real-world data
Selected Articles
1. Comparative effectiveness of continuous positive airway pressure and glucagon-like peptide-1 receptor agonists in obstructive sleep apnea: A network meta-analysis of randomised trials.
Across 34 randomized trials (n=3964), CPAP yielded the greatest AHI reduction and improved daytime sleepiness (ESS). GLP-1 RAs, particularly liraglutide, primarily reduced BMI, highlighting complementary effects on OSA pathophysiology and metabolic comorbidity.
Impact: This network meta-analysis clarifies modality-specific benefits in OSA, separating airway mechanics (CPAP) from metabolic modulation (GLP-1 RAs), guiding patient-centered, combined strategies.
Clinical Implications: CPAP remains the first-line intervention for AHI reduction and symptom control, while GLP-1 RAs can be considered to address obesity-related metabolic risk. Clinicians may tailor combined approaches in OSA with obesity/diabetes to target both airway obstruction and weight/metabolic outcomes.
Key Findings
- CPAP produced the largest AHI reduction vs no intervention (MD −22.17 events/h; 95% CI −38.01 to −6.33).
- CPAP improved daytime sleepiness (ESS MD −2.75; 95% CI −3.71 to −1.79).
- Liraglutide significantly reduced BMI (MD −1.60 kg/m2), supporting metabolic benefits alongside OSA care.
Methodological Strengths
- Network meta-analysis integrating 34 randomized trials with SUCRA ranking and GRADE certainty assessment
- Evaluation of multidimensional endpoints (AHI, ESS, BMI, BP, glycemia) enabling modality-specific inference
Limitations
- Heterogeneity in trial designs, durations, and patient characteristics across interventions
- Limited direct evidence for combined CPAP plus GLP-1 RA strategies and long-term outcomes
Future Directions: Prospective trials should test combined CPAP–GLP-1 RA strategies, assess long-term cardiometabolic and neurocognitive outcomes, and define subgroups (e.g., severe obesity, diabetes) most likely to benefit.
To compare the effects of continuous positive airway pressure (CPAP), glucagon-like peptide-1 receptor agonists (GLP-1 RAs), their combination, and no active intervention on respiratory, sleepiness, and metabolic outcomes in adults with obstructive sleep apnea (OSA). We searched PubMed, Embase, and CENTRAL through August 2025 for randomised trials of CPAP, exenatide, liraglutide, tirzepatide, or their combinations. The primary endpoint was apnea-hypopnea index (AHI). Secondary endpoints were Epworth Sleepiness Scale (ESS), body mass index (BMI), systolic and diastolic blood pressure (SBP, DBP), fasting glucose, and glycated haemoglobin (HbA1c). Random-effects network meta-analyses estimated mean differences (MDs) with 95% confidence intervals (CIs). Treatments were ranked using SUCRA, and certainty of evidence was assessed with GRADE. Thirty-four trials including 3964 participants were eligible. CPAP produced the largest reduction in AHI versus no active intervention (MD -22.17 events/h; 95% CI -38.01 to -6.33) and improved ESS (MD -2.75; 95% CI -3.71 to -1.79). Liraglutide reduced BMI (MD -1.60 kg/m
2. Combined effect of MASLD and low muscle strength on the risk of osteoporotic fractures: A UK Biobank cohort study.
In 191,176 adults followed for a median 13.4 years, MASLD alone did not increase osteoporotic fracture risk, whereas low muscle strength did; the highest risk occurred when MASLD coexisted with low muscle strength, especially in women.
Impact: This study decouples MASLD from fracture risk unless low muscle strength coexists, refocusing skeletal risk assessment toward muscle function in MASLD populations.
Clinical Implications: In MASLD, routine assessment of muscle strength (e.g., handgrip) should be integrated into fracture risk evaluation. Interventions to improve muscle strength may mitigate fracture risk more than liver-directed strategies alone.
Key Findings
- MASLD alone was not associated with higher osteoporotic fracture risk (aHR 1.00, 95% CI 0.90–1.10).
- Low muscle strength alone increased fracture risk (aHR 1.14, 95% CI 1.06–1.22).
- Combined MASLD and low muscle strength conferred the highest risk (aHR 1.23, 95% CI 1.10–1.38), particularly in women.
Methodological Strengths
- Very large prospective cohort with long median follow-up (13.4 years)
- Standardized definitions and Cox models with adjustment, including subgroup analyses by sex
Limitations
- MASLD defined by FLI and metabolic risk factors rather than imaging or biopsy
- Residual confounding and potential misclassification inherent to observational design
Future Directions: Interventional trials should test whether resistance training and muscle-strengthening strategies reduce fracture incidence in MASLD, and validate risk models integrating muscle metrics.
BACKGROUND: The relationship between metabolic dysfunction-associated steatotic liver disease (MASLD) and osteoporotic fractures risk remains controversial. Low muscle strength (LMS), a key component of sarcopenia and an established fracture risk factor, frequently coexists with MASLD, yet their combined effect on skeletal health is unclear. This study examined the individual and combined effects of MASLD and LMS on osteoporotic fracture risk. METHODS: This large-scale cohort study utilized UK Biobank data. MASLD was defined as a Fatty Liver Index (FLI) ≥ 60 plus at least one metabolic risk factor. LMS was defined as a maximum handgrip strength Z-score < -0.5, standardized for age and sex. Participants were categorized into: (1) Control (no MASLD/no LMS), (2) LMS only, (3) MASLD only, and (4) MASLD with LMS. The primary outcome was incident osteoporotic fractures. Cox proportional hazards models estimated hazard ratios (HRs) and 95% confidence intervals (CIs). RESULTS: A total of 191,176 participants were included. Over a median follow-up of 13.4 years, 4,919 fracture events occurred (median age 57 years; women, 52.1%). Compared with controls, MASLD alone was not associated with higher fracture risk (aHR 1.00, 95% CI 0.90-1.10), unlike LMS alone (aHR 1.14, 95% CI 1.06-1.22). Participants with both MASLD and LMS, particularly women, had the greatest fracture risk (aHR 1.23, 95% CI 1.10-1.38). CONCLUSION: Fracture risk in individuals with MASLD was increased only when LMS coexisted. These findings highlight the importance of incorporating muscle health assessment into the clinical evaluation of MASLD to improve risk stratification.
3. Real-world predictors of progression to type 2 diabetes among adults with prediabetes.
In 39,281 cases and 58,751 controls with prediabetes, middle age (35–64), obesity, CVD, OSA, MASH, and neuropathy were associated with higher odds of progression to T2D; Black and Hispanic patients had greater risk than White patients.
Impact: The study leverages large-scale, linked real-world data to identify modifiable comorbidities and disparities that can target prevention of T2D in high-risk prediabetes populations.
Clinical Implications: Clinicians should intensify preventive interventions in prediabetes patients aged 35–64 and those with obesity, CVD, OSA, MASH, or neuropathy, and prioritize outreach to Black and Hispanic populations to reduce progression risk.
Key Findings
- Age 35–44 (OR 1.37), 45–54 (OR 1.49), 55–64 (OR 1.33) vs 18–34 increased odds of T2D progression.
- Obesity (OR 1.45), CVD (OR 1.64), OSA (OR 1.36), MASH (OR 1.37), and neuropathy (OR 1.19) were associated with progression.
- Black (OR 1.27) and Hispanic (OR 1.21) patients had greater odds of progression vs White patients.
Methodological Strengths
- Very large, contemporary, multi-year dataset linking claims and EMR
- Robust multivariable modeling with stratified assessments by sex and race/ethnicity
Limitations
- Observational case-control design limits causal inference; potential misclassification in administrative data
- Race/ethnicity data available for only 62% of participants
Future Directions: Prospective risk tools integrating comorbidities (OSA, MASH) and social determinants should be validated; pragmatic trials should test targeted prevention bundles in high-risk subgroups.
AIMS: Assess predictors of progression to type 2 diabetes (T2D) among patients with prediabetes. MATERIALS AND METHODS: This case-control study assessed adults with prediabetes using US claims and EMR-linked data from January 1, 2016, through January 31, 2024. T2D cases were patients with prediabetes who progressed to T2D (index: date of first T2D diagnosis); controls had prediabetes but did not progress to T2D. Control index dates were randomly assigned from cases. Demographic and clinical characteristics in the year before progression to T2D were assessed to identify progression predictors. RESULTS: The study included 39 281 T2D cases and 58 751 controls. Data on race/ethnicity (White, Black, Hispanic, Asian-Other) were available for 62% of the study sample. Demographic characteristics for cases and controls were similar in the overall population, by sex, and by race/ethnicity. During the 1-year baseline, T2D cases had a higher prevalence of obesity, cardiovascular disease (CVD), and obstructive sleep apnea (OSA) than controls. Comorbidity patterns varied by sex and race/ethnicity. Compared with patients aged 18-34 years, patients aged 35-44 (OR, 1.37), 45-54 (OR, 1.49), and 55-64 (OR, 1.33) had higher odds of progression. Obesity (OR, 1.45), CVD (OR, 1.64), OSA (OR, 1.36), metabolic dysfunction-associated steatohepatitis (MASH; OR, 1.37), and neuropathy (OR, 1.19) were associated with T2D progression. Black (OR, 1.27) and Hispanic (OR, 1.21) patients had higher odds of progression than White patients (all p < 0.0001). CONCLUSIONS: Among patients with prediabetes, age 35-64 years, obesity, CVD, OSA, MASH, and neuropathy in the year before progression are associated with progression to T2D. PLAIN LANGUAGE SUMMARY: What is the context and purpose of this research study? This research study looked at why some adults with prediabetes were more likely than others to develop type 2 diabetes (T2D). The researchers wanted to know if factors like age, sex, race, history of health conditions (such as obesity, heart disease, and sleep disorders), and abnormal lab tests (like elevated blood sugar levels) could predict who will get T2D. What was done? The researchers conducted a study using a US database of insurance and medical records from 2016 to 2024. The researchers compared two groups: 39 281 adults with prediabetes who developed T2D and 58 751 adults with prediabetes who did not develop T2D. The researchers looked for patterns in these groups and used statistics to identify risk factors. What were the main results? The study found that middle-aged adults (35-64 years old) and those with health problems like obesity, heart disease, sleep apnea, neuropathy, and liver disease were more likely to get T2D. These patterns were similar across patients of different races and genders. However, Black and Hispanic patients had a higher risk of T2D compared to White patients. There was no difference in the risk of developing T2D between patients with Asian or Other ethnicities and White patients. What is the originality and relevance of this study? This study is important because it identifies factors that increase the risk of developing T2D in people with prediabetes. It suggests that age, certain health conditions, and race can affect this risk. These findings can help doctors create better treatment and prevention plans for high-risk patients.